Back to discover
Disease
Alzheimer's disease type 1
Late-stage therapeutic development
Also known as AD1, Alzheimer disease 1, familial, Alzheimer disease, familial, 1, AD+2 more
AD1, Alzheimer disease 1, familial, Alzheimer disease, familial, 1, AD, Alzheimer disease 1, early-onset familial form of Alzheimer disease.
24
Clinical trials
5
Associated genes
1
Related proteins
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q4 2028.
Upcoming Milestones
- Q4 2028AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
- Q2 2029A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
- Q2 2029A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above
- Q2 2029A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
- Q3 2029An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20292026-10-14
Upcoming trial readoutHigh impact
Results expected Q2 20292026-10-07
Clinical MilestonesView all 14Hide
Results posted
- 2026-04-16Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's DiseaseResults posted
- 2026-02-24A Randomised Double-blind Placebo-controlled Clinical Study Investigating the Effects of Semaglutide s.c. Once-weekly Versus Placebo on Central and Peripheral Inflammation in Participants With Alzheimer's DiseaseResults posted
Results expected
- 2026-10-14A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or AboveResults expected Q2 2029
- 2026-10-07A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional DeclineResults expected Q2 2029
- 2026-07-27The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's DiseaseResults expected Q2 2030
- 2026-07-07An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACMResults expected Q3 2029
- 2026-06-04AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)Results expected Q4 2028
Recently completed
- 2026-05-12Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's DiseaseCompleted
- 2026-01-30A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)Completed
- 2026-01-30A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)Completed
Other updates
- 2026-04-01Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's DiseaseWithdrawn
- 2026-03-11Long-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 GenotypeTerminated
- 2026-01-06A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin GeneTerminated
+6 more in the activity timeline below
Activity timeline14
- 2026-10-14ClinicalA Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or AboveResults expected Q2 2029
- 2026-10-07ClinicalA Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional DeclineResults expected Q2 2029
- 2026-07-27ClinicalThe Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's DiseaseResults expected Q2 2030
- 2026-07-07ClinicalAn Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACMResults expected Q3 2029
- 2026-06-04ClinicalAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)Results expected Q4 2028
- 2026-05-12ClinicalAssessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's DiseaseCompleted
- 2026-04-16ClinicalBiomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's DiseaseResults posted
- 2026-04-07ClinicalA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's DiseaseResults expected Q2 2029
- 2026-04-01ClinicalHistidine Oral Supplementation as a Therapeutic Modality for Alzheimer's DiseaseWithdrawn
- 2026-03-11ClinicalLong-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 GenotypeTerminated
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recently completed
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
AD1, Alzheimer disease 1, familial, Alzheimer disease, familial, 1, AD, Alzheimer disease 1, early-onset familial form of Alzheimer disease
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.